High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases-Reference-Cited by-同舟云学术

High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases

Published:2020-11-12 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Laganà Marta,Gurizzan Cristina,Roca Elisa,Cortinovis Diego,Signorelli Diego,Pagani Filippo,Bettini Anna,Bonomi Lucia,Rinaldi Silvia,Berardi Rossana,Filetti Marco,Giusti Raffaele,Pilotto Sara,Milella Michele,Intagliata Salvatore,Baggi Alice,Cortellini Alessio,Soto Parra Hector,Brighenti Matteo,Petrelli Fausto,Bennati Chiara,Bidoli Paolo,Garassino Marina Chiara,Berruti Alfredo

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference29 articles.

1. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women;Malvezzi;Ann Oncol,2015

2. Non-small cell lung cancer: current treatment and future advances;Zappa;Transl Lung Cancer Res,2016

3. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma;Mok;N Engl J Med,2009

4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

5. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial;Wu;Lancet Oncol,2014

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma;European Journal of Cancer;2024-09

2. A case of response to combination treatment with TSA-DC-CTL immunotherapy and osimertinib in EGFR mutated advanced lung adenocarcinoma;Molecular Cancer;2024-08-09

3. Single-molecule targeted therapy shrinks lung lesions and improves bone metastases: A case report;Medicine;2024-07-19

4. Assessing EGFR‐mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy;Cancer Medicine;2024-03-29

5. Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib;JTO Clinical and Research Reports;2023-05